StreetAlpha.app
Home › Stocks › MIRM

Mirum Pharmaceuticals, Inc. (MIRM)

Healthcare
$91.95
▲ +0.40%
LAST CLOSE · NOV 17

Mirum develops and sells medicines for rare liver and other rare diseases, based in Foster City, California. It last closed at $91.95 on Nov 17, up 0.40% on the day. MIRM last reported earnings on Tue, Nov 3, 2026. The average 12-month price target from 10 analysts is $160.20 (+74.2% from the last close), with a high of $202.00 and a low of $130.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (10 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $719K, the largest $719K.

AI Auto Pilots
Is MIRM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$670.8M
+42.2% vs a year ago
Net income
−$903.9M
−134.8% margin
EPS (diluted)
−$14.47
Free cash flow
−$273.9M
−40.8% margin
Valuation
Market cap
$6.0B
65.3M shares
P/E
–
No P/E while losing money
Price to sales
8.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$243.2M
At Sep 30
Debt
$731.3M
At Sep 30
Shareholder equity
−$54.2M
Shares outstanding
65.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $19.1M$19.1MFY2021FY2022: $77.1M$77.1MFY2022FY2023: $186.4M$186.4MFY2023FY2024: $336.9M$336.9MFY2024FY2025: $521.3M$521.3MFY2025

From MIRM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Last report
Nov 3
2026 · After the close (AMC)
Reported EPS
-$0.87
vs -$0.53 est. · miss
Year-ago EPS
$0.05
Same quarter last year
Options-implied move
±10.0%
Priced in before that report
Analyst consensus
Strong Buy
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
10firms
10 Buy0 Hold0 Sell
Each firm's latest rating on MIRM in the past 90 days
Average 12-month target
$160.20
▲ 74.2% upside

Based on 10 analysts who set a price target on MIRM in the past 90 days. The average target is $160.20, with a high of $202.00 and a low of $130.00, compared with the last close of $91.95.

Low $130.00Avg $160.20High $202.00
Blue marker: last close $91.95
Highest target$202.00
Average target$160.20
Lowest target$130.00
Latest rating changes
CitigroupTarget raised
Nov 11Buy$184 → $194
Leerink PartnersMaintained
Nov 5Buy$140
CitizensTarget raised
Nov 4Buy$137 → $167
HC Wainwright & Co.Target raised
Nov 4Buy$200 → $202
Cantor FitzgeraldMaintained
Nov 4Buy$160
DateFirmActionRatingPrice target
Nov 11CitigroupTarget raisedBuy$184 → $194
Nov 5Leerink PartnersMaintainedBuy$140
Nov 4CitizensTarget raisedBuy$137 → $167
Nov 4HC Wainwright & Co.Target raisedBuy$200 → $202
Nov 4Cantor FitzgeraldMaintainedBuy$160
Loading…

Technical Analysis

MIRM · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 3% above its 20 day and 4% above its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 55). The nearest support is the Pivot at $91.21, and the nearest resistance the Pivot R1 at $93.05.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityNormal, 4.2%/day
Key levels
$130.0052 week high+41.4%
$98.97Swing high (Nov 5)+7.6%
$98.51100 day average+7.1%
$98.29200 day average+6.9%
$93.05Pivot R1+1.2%
$91.95Last close
$91.21Pivot−0.8%
$90.59Swing low (Jun 3)−1.5%
$90.12Pivot S1−2.0%
$89.1520 day average−3.0%
$88.4550 day average−3.8%
$63.2352 week low−31.2%
Indicators
RSI (14)54.87Middle of its rangeNeutral
MACD1.84Above its signal lineBullish
Stochastic59.8Middle of its rangeNeutral
ADX (14)24.7Weak trend
Williams %R-44.3Oversold below −80, overbought above −20Neutral
CCI (20)34.8Oversold below −100, overbought above 100Neutral
Rate of change+5.7%Change over 10 sessionsBullish
ATR (14)$3.82Typical daily range, 4.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for MIRM

What happened before

See how MIRM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MIRM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MIRM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MIRM in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$719K
Largest print
$719K
Loading…

MIRM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●173 buying vs 152 selling
  • ▲Held by funds +0.7 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding320331−3.3%
In funds' top 101020−50.0%
Held by funds110.3%109.6%+0.7 pts
New / increased49 / 12459 / 126−6.5%
Reduced / sold out96 / 56102 / 45+3.4%
Put/call ratio0.453.30−86.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MIRM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIRM is in one of them and how their past MIRM trades turned out.

MIRM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MIRM in an article yet. Here's the latest on the wider market.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company based in Foster City, California, that develops and sells medicines for rare diseases, mainly rare liver conditions. Its approved products are Livmarli, used to treat severe itching in certain rare cholestatic liver diseases, and Cholbam and Ctexli, used for bile acid disorders and a rare brain and tendon condition. It sells these medicines mainly in the United States and through partners in other countries, and it is developing treatments for other rare liver diseases and a rare genetic neurological disorder. Its customers include patients, physicians and specialty pharmacies.

Headquarters
Foster City, CA
Founded
2018